证券代码：300797 证券简称：钢研纳克 公告编号：2025-027 钢研纳克检测技术股份有限公司 关于首期限制性股票激励计划首次授予部分第二个解除限售期 解除限售条件成就的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 股票数量为 3,172,950 股，占目前公司总股本的 0.8289%。 请投资者注意。 ）于 2025 年 6 月 27 日召开第三届 钢研纳克检测技术股份有限公司（以下简称"公司" 董事会第七次会议、第三届监事会第七次会议，审议通过了《关于首期限制性股票激励计划 首次授予部分第二个解除限售期解除限售条件成就的议案》 ，根据公司《首期限制性股票激 励计划（修订稿）》的相关规定，董事会认为，公司首期限制性股票激励计划（以下简称"本 激励计划"）首次授予部分限制性股票第二个解除限售期解除限售条件已成就，同意对首次 授予的 97 名激励对象第二个解除限售期的 3,172,950 股限制性股票进行解除限售，具体情 况如下： 一、限制性股票激励计划实施简述 纳克检测技术股份有限公司首期限制性股票激励计划（草案）>及其摘要的议案 ...

Core Viewpoint - The report discusses the achievement of the conditions for the second unlock period of the first grant of restricted stock and the first unlock period of the reserved grant under the stock incentive plan of Steel Research Nake Testing Technology Co., Ltd. [3][6][29] Group 1: Stock Incentive Plan Overview - The stock incentive plan involves granting restricted stocks to employees, with specific unlock conditions and periods defined [3][4] - The first grant of restricted stocks was completed on July 1, 2022, with a total of 6,810,000 shares granted [9] - The second unlock period for the first grant is set to occur between 36 to 48 months after the initial grant [15][16] Group 2: Unlock Conditions - For the second unlock period, 33% of the granted shares can be unlocked if certain conditions are met, including the absence of adverse audit opinions and the fulfillment of performance targets [15][18] - The performance target for the year 2023 includes achieving a net profit of RMB 138,649,481.39, representing a compound annual growth rate of 21.54% from 2020 [19][25] Group 3: Reserved Grant Details - The reserved grant's first unlock period is defined as 24 to 36 months after the completion of the grant registration, with a similar unlock ratio of 33% [23][25] - The performance targets for the reserved grant are aligned with the overall company performance metrics, ensuring that the conditions for unlocking are consistent with the company's financial health [25][29] Group 4: Independent Financial Advisor's Opinion - The independent financial advisor confirms that the conditions for both the second unlock period of the first grant and the first unlock period of the reserved grant have been met, complying with relevant laws and regulations [20][29] - The advisor emphasizes the need for the company to disclose information and complete necessary procedures with the Shenzhen Stock Exchange following the unlock [20][29]

证券代码：603153 证券简称：上海建科 公告编号：2025-034 上海建科咨询集团股份有限公司 关于 2024 年度暨 2025 年第一季度业绩说明 会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 ）于 2025 年 上海建科咨询集团股份有限公司（以下简称"公司" 上午 10:00-11:00 在价值在线网络平台召开了 2024 年度暨 2025 年第一季度业绩说明会，现将活动情况公告如下： 一、业绩说明会召开情况 时间：2025 年 6 月 27 日（星期五）上午 10:00-11:00 地点：价值在线（网址：www.ir-online.cn） 答：2024 年度，公司围绕"提质增效"的年度工作总基调，积 极应对外部困难挑战，持续推进深化改革，集聚创新发展动能，聚力 拓展市场空间， 促进各项经济指标稳步增长，全年实现营业收入 41.52 亿元，同比增长 3.54%；归母净利润 3.43 亿元，同比增长 8.49%；扣 非后归母净利润 2.76 亿元，同比增长 16.46%，总体完成年初确定的 各项目 ...

Core Viewpoint - Jiangsu Kangwei Century Biotechnology Co., Ltd. is undergoing scrutiny regarding its business performance and financial disclosures, particularly focusing on its main business segments and the reasons behind revenue and cost fluctuations in 2024 [1][2]. Business Overview - The company's main business includes molecular detection reagents, nucleic acid extraction reagents, nucleic acid preservation reagents, and testing services [1]. - In 2024, the sales volume of molecular detection reagents increased by 34%, while nucleic acid extraction reagents saw a decline of 15%, and nucleic acid preservation reagents surged by 67% [1]. Revenue and Sales Analysis - The revenue, sales volume, and price changes for various product types in 2024 are as follows: - Molecular detection reagents: Sales volume of 60,984.04 million units, revenue of 5,870.64 million yuan, and a price increase of 15.16% [3]. - Nucleic acid extraction reagents: Sales volume of 1,691.71 million units, revenue of 2,448.73 million yuan, with a price increase of 8.17% [4]. - Nucleic acid preservation reagents: Sales volume of 1,297.61 million units, revenue of 2,802.23 million yuan, but a price decrease of 24.07% [4]. Customer Segmentation - The customer base for molecular detection reagents primarily consists of industrial clients, with sales to this segment increasing by 11.78% in revenue [4]. - Sales to distributors decreased by 15.39%, indicating a competitive market environment affecting pricing and sales volume [4]. Market Dynamics - The overall increase in sales volume for molecular detection reagents and nucleic acid preservation reagents is attributed to the company's ongoing market expansion and new product development [7]. - The decline in sales volume for nucleic acid extraction reagents is linked to increased application of non-extraction testing technologies by industrial clients, leading to reduced demand [7]. Cost and Material Analysis - The increase in direct material costs outpaced revenue growth due to product upgrades and market promotion strategies, resulting in a 6.41% increase in direct materials compared to a 2.25% decline in sales revenue [8]. - The overall pricing pressure in the molecular detection market has contributed to the disparity between revenue growth and material cost increases [8]. Bad Debt and Financial Health - The company reported a significant increase in bad debt losses, amounting to 0.44 billion yuan, with a notable rise in single-item provisions for bad debts [9]. - The increase in bad debt is primarily due to delayed payments from government units and enterprises related to testing services during public health events [10]. Investment Activities - In March 2024, the company acquired a 51% stake in Shanghai Haoweitai for 12.75 million yuan, with the acquisition date net assets valued at 26 million yuan [11]. - The acquisition of Guangzhou Kangjian was justified by the strategic need to enhance local operations and expand service offerings in the molecular testing market [12][14].

中国国际金融股份有限公司 变更部分募投项目实施主体、实施地点的核查意见 中国国际金融股份有限公司（以下简称"保荐机构"）作为西安高压电器研究院股 份有限公司（以下简称"西高院"或"公司"）首次公开发行股票并在科创板上市的保 荐机构，根据《证券发行上市保荐业务管理办法》《上市公司募集资金监管规则》《上 海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 更部分募投项目实施主体、实施地点事项进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意西安高压电器研究院股份有限公司首次公开 发行股票注册的批复》（证监许可〔2023〕726 号）同意注册，并经上海证券交易所同 意，公司首次公开发行人民币普通股（A 股）股票 7,914.4867 万股，每股发行价格为人 民币 14.16 元，募集资金总额为人民币 112,069.13 万元，扣除发行费用（不含增值税） 人民币 6,090.83 万元，实际募集资金净额为人民币 105,978.30 万元。上述资金已全部到 位，天职国际会计师事务所（特殊普通合伙）对本次公开发行股票的募集资金到位情况 进行了审验，并于 20 ...

证券代码：603060 证券简称：国检集团 债券代码：113688 债券简称：国检转债 中国国检测试控股集团股份有限公司 （住所：北京市朝阳区管庄东里 1 号科研生产区南楼） 中国国检测试控股集团股份有限公司 向不特定对象发行可转换公司债券 受托管理事务报告 （2024 年度） 债券受托管理人 （住所：北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层） 二〇二五年六月 重要声明 本报告依据《公司债券发行与交易管理办法》（以下简称《管理办法》）、 《公司债券受托管理人执业行为准则》（以下简称《执业行为准则》）、证券交 易所公司债券上市规则（以下简称"上市规则"）、发行人与中国国际金融股份 有限公司（以下简称"中金公司"或"受托管理人"）签订的债券受托管理协议 （以下简称"受托管理协议"）及其它相关信息披露文件以及中国国检测试控股 集团股份有限公司（以下简称"发行人"或"公司"）出具的相关说明文件和提 供的相关资料等，由受托管理人中金公司编制。中金公司编制本报告的内容及信 息均来源于中国国检测试控股集团股份有限公司提供的资料或说明。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者 ...

Group 1 - Hengbang Co., Ltd. plans to establish a joint venture with Huasheng Development with a registered capital of 10 million yuan, where Hengbang will contribute 8 million yuan (80%) and Huasheng will contribute 2 million yuan (20%) [1] - Hunan Gold's subsidiary Anhua Zhazi Creek Smelting Plant will undergo temporary maintenance starting from the end of June 2025, expected to last no more than 30 days [2] - Defu Technology's subsidiary signed supply agreements for lithium battery copper foil products with two leading global companies, with contract durations of 3 years and 5 years respectively [3] Group 2 - Binjiang Group won the rights to two residential land parcels for a total price of 4.368 billion yuan [5] - Zhong'an Technology announced the resignation of its executive vice president and board secretary due to personal reasons [7] - Changqing Technology's project for special polymer materials and electronic materials has officially commenced production, adding a capacity of 120,500 tons per year [10] Group 3 - Gansu Energy received approval from the China Securities Regulatory Commission to publicly issue bonds totaling up to 2 billion yuan [10] - Shuoshi Biology obtained a medical device registration certificate for an in vitro diagnostic reagent, valid until June 2030 [12] - Yawen Co., Ltd. plans to issue shares to specific investors, with the application accepted by the Shenzhen Stock Exchange [13] Group 4 - Guoyao Modern's subsidiary received approval for the listing of a raw material drug, which is a selective anticholinergic agent [16] - Inner Mongolia First Machinery's subsidiary signed a railway freight car procurement contract worth 130 million yuan [18] - Xining Special Steel plans to raise up to 1 billion yuan through a private placement to its controlling shareholder [39] Group 5 - Huadong Medicine's subsidiary received approval for a clinical trial of a new injectable drug targeting advanced solid tumors [29] - Warner Pharmaceutical's compound potassium hydrogen phosphate injection passed the consistency evaluation for generic drugs [30] - North Special Technology plans to raise up to 300 million yuan through a private placement for a production base project in Thailand [30] Group 6 - Xiangyang Technology is the first candidate for a 533 million yuan Airbus project [45] - Haishun New Materials intends to acquire 100% of Guangdong Zhengyi Packaging [46] - Jida Zhengyuan's shareholder plans to reduce their stake by up to 0.73% due to personal financial needs [47]

上海国缆检测股份有限公司投资者关系活动记录表 | 投资者关系活动 | ☑特定对象调研 □分析师会议 □媒体采访 □业绩说明会 | | --- | --- | | | □新闻发布会 □路演活动 | | 类别 | □现场参观 | | | □其他（请文字说明其他活动内容） | | | 银河证券 王艳 | | 参与单位名称及 | 义柏资本 姜嘉伟 | | | 东北证券 唐凯 | | 人员姓名 | 沣沃资本 赵静 | | | 稠州银行 刘俊 | | 时间 | 2025 年 6 月 26 日 | | 地点 | 公司会议室 | | | 董事会秘书：王晨生 | | 上市公司接待人 | 证券事务代表：王俊 | | 员姓名 | 证券事务专员：李雯 | | | 公司简介： | | | 国缆检测业务起源于 1983 年上海电缆所成立的线缆检测中心， | | | 作为国内最早开展线缆检验检测的机构之一，公司是中国电工行业首 | | | 张检测机构认可证书（证书编号：电检字 001）获得机构，亦是首家 | | | 获得国家级线缆质检中心授权的检测机构，公司目前为国有控股企 | | | 业。 | | | 公司主营业务为电线电缆及光纤光缆的 ...

随着华中地区检测业务需求快速增长，武汉实验室亟需"扩容升级"。华中总部建成后， 业务将覆盖船舶、航空航天、新能源汽车及半导体等领域，提供安全测试、材料分析及集成 电路失效分析等服务，成为企业新增长引擎。 苏试试验集团董事长钟琼华表示，该总部是公司服务国家战略与市场需求的重要布局， 将整合试验服务、设备研发及区域运营功能，增强对华中乃至全国高端制造产业集群的支撑 能力。他特别点赞武汉经开区营商环境，称从审批到开工均获高效支持，充分体现"车谷速 度"。 武汉经开区作为国家级"两业融合"试点区，近年来重点发展检验检测等生产性服务业。 此前，武汉生产服务型国家物流枢纽已落户该区。经开区相关负责人表示，该项目将提升区 域在新能源汽车、半导体等领域的检测服务能力，政府将持续优化服务，推动项目早投产见 效，打造行业标杆。 编辑：熊展平 6月26日，苏州苏试试验集团股份有限公司华中总部项目在武汉经开区开工建设，为武 汉加快建设国家检验检测高技术产业集聚区注入新动能。 该项目选址武汉经开区智能制造产业园，第一阶段将建设研发大楼及试验场地，预计 2026年12月前完成厂房建设，年底实验室投入运营。后续还将建设新能源汽车、船舶、宇 ...

Q&A 日联科技 20260626 摘要 瑞凌科技已构建全系列 X 射线检测产品矩阵，包括闭管、开管及大功率 X 射线源，2024 年推出 180 千瓦 B 型 X 射线管等新品，并计划在 2025 年扩大生产规模，满足市场对高精度和高穿透性检测的需求。 公司通过国内外六大研发生产基地实现全球化布局，国内基地侧重核心 部件及不同类型设备的生产，海外基地则服务当地客户及头部厂商，提 升全球市场响应速度和竞争力。 瑞凌科技下游应用领域广泛，涵盖集成电路、电子制造、新能源电池、 焊接及材料检测等，并积极拓展食品异物检测、汽车零部件、航空军工 等新应用场景，降低对单一行业的依赖。 2025 年 1-4 月新增订单同比翻番，预计上半年订单接近翻番，受益于 消费电子和锂电产业回暖，以及核心部件 X 光管技术的提升，显著扩大 了业务范围和客户群体。 公司一季度应收账款增长 40%，存货增长 20%，合同负债增长 26%， 固定资产增长 35%，表明业务扩张，对全年业绩具有积极影响，订单转 化周期平均为一到两个季度，集成电路类订单转化较快。 今年（2025 年），之前较为低迷的消费电子和锂电产业出现了显著改善。自 2022 ...